Lexicon Pharma (LXRX) Tops Q1 EPS by 5c
Tweet
Share
E-mail
Get Alerts LXRX Hot Sheet
Price: $2.35 --0%
Financial Fact:
Consolidated net loss per common share, basic and diluted: -0.35
Today's EPS Names:
VAXX, NMRD, EGRX, More
Financial Fact:
Consolidated net loss per common share, basic and diluted: -0.35
Today's EPS Names:
VAXX, NMRD, EGRX, More
Join SI Premium – FREE
Lexicon Pharma (NASDAQ: LXRX) reported Q1 EPS of ($0.07), $0.05 better than the analyst estimate of ($0.12). Revenue for the quarter came in at $1.26 million versus the consensus estimate of $2.82 million.
For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Karyopharm Therapeutics (KPTI) Misses Q2 EPS by $1.01, Beats on Revenue; Offers FY26 Revenue Guidance
- ADC Therapeutics SA (ADCT) Tops Q2 EPS by 11c
- CorMedix (CRMD) Tops Q2 EPS by 6c; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
